Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1996-06-21
1999-03-09
Cook, Rebecca
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
A61K 31475
Patent
active
058801332
ABSTRACT:
Pharmaceutical formulations of Highly Lipophilic Camptothecin Derivatives (HLCD) include HLCD dissolved in N-methyl Pyrrolidinene (NMP). The formulations also include quantities of pharmaceutically acceptable excipients and diluents incorporated thereinto.
REFERENCES:
patent: 4473692 (1984-09-01), Miyasaka et al.
patent: 4772589 (1988-09-01), Kaplan et al.
patent: 4778891 (1988-10-01), Tagawa et al.
patent: 5034397 (1991-07-01), Kaplan et al.
patent: 5061800 (1991-10-01), Yaegashi et al.
patent: 5422361 (1995-06-01), Munayyer et al.
patent: 5447936 (1995-09-01), Hausheer et al.
patent: 5468754 (1995-11-01), Hausheer et al.
patent: 5573781 (1996-11-01), Brown et al.
Barilero, et al., Simultaneous determination of the camptothecin analogue CPT-11 and its active metabolite SN-38 by high-performance liquid chromatography: application to plasma pharmacokinetic studies in cancer patients, Journal of Chromatography, 575 (1992) 275-280.
Bates, T. et al., Solubilizing Properties of Bile Salt Solutions I. Effect of Temperature and Bile Salt Concentration on Solubilization of Glutethimide, Griseofulvin, and Hexestrol. Journal of Pharmaceutical Sciences 55:191-199, (1966).
Bates, T. et al., Rates of Dissolution of Griseofulvin and Hexestrol in Bile Salt Solutions, Chemical Abstracts, 65:8680b, 1966.
Bates, et al., Solubilizing Properties of Bile Salt Solutions on Glutethimide, Griseofulvin, and Hexestrol. Chem. Abstracts 64: 9517e 1966; 65:15165a, 1966.
Clavel, M. et al., Phase I Study of the Camptothecin Analoigue CPT-11, Administered Daily for 3 Consecutive Days. Proc. Amer. Assoc. Cancer Res. 3:83, 1992.
Creaven, P.J. et al., Plasma Camptothecin (NSC-100880) Levels During a 5-Day Course of Treatment: Relation to Dose and Toxicity. Cancer Chem. Rep. 56: 573-578, 1972.
Culine, S., Phase I Study of the Camptothecin Analog CPT-11, Using a Weekly Schedule. Proc. Of Amer. Soc. Clin. Onc. 11:110, 1992.
Emerson, D.L., In Vivo Antitumor Activity of Two New Seven-substituted Water-soluble Camptothecin Analogues. Cancer Research. 55: 603-609, 1995.
Fukuoka, M. et al., A Phase II Study of CPT-11, A New Derivative of Camptothecin, for Previously Untreated Small-Cell Lung Cancer. J. Clin. Onc. 10(1): 16-20, 1992.
Giovanella, B.C., et al. DNA Topoisomerase I--Targeted Chemotherapy of Human Colon Cancer in Xenografts. Science 246: 1046-1048; 1989.
Gottlieb, J.A. et al., Preliminary Pharmacologic and Clinical Evaluation of Camptothecin Sodium (NSC-100880). Cancer Chem. Rep. 54: 461-470, 1970.
Gottlieb, J.A. et al., Treatment of Malignant Melanoma with Camptothecin (NSC-100880). Cancer Chem. Rep. 56: 103-105, 1972.
Hsiang et al., Arrest of Replication Forks by Drug-stabilized Topoisomerase I-DNA Cleavable Complexes as a Mechanism of Cell Killing by Camptothecin Analogues. Cancer Res. 49:5077-5082, 1989.
Houghton, P.J: et al., Therapeutic Efficacy of the Topoisomerase I cin against Human Tumor Xenografts: Lack of Cross-Resistance in Vivo in Tumors with Acquired Resistance to the Topoisomerase I Inhibitor 9-Dimethylaminomethyl-10-hydroxycamptothecin. Cancer Res. 53:2823-2829, 1993.
Jaxel, C. et al., Structure Activity Study of the Actions of Camptothecin Derivatives on Mammalian Topoisomerase I: Evidence for a Specific Receptor Site and a relation to Antitumor Activity. Cancer Res. 49: 1465-1469, 1989.
Kaneda, N. et al., Metabolism and Pharmacokinetics of the Camptothecin Analogue CPT-11 in the Mouse. Cancer Research 50:1715-1720, 1990.
Kano, Y., et al., Effects of CPT-11 in Combination with other Anti-Cancer Agents in Cluture. Int. J. Cancer 50:604-610; 1992.
Kanzawa, F., et al., Role of Carboxylesterase on Metaolism of Camptothecin Analog (CPT-11) in Non-Small Cell Lung Cancer Cell Line PC-7 Cells (Meeting Abstract). Proc. Annual Meet. Am. Assoc. Cancer Res. 33:A2552; 1992.
Kawato, Y., et al., Intracellular Roles of SN38, a Metabolite of the Camptothecin Derivative CPT-11, in the Antitumor Effect of CPT-11. Cancer Res. 51:4187-4191, 1991.
Kunimoto, T. et al., Antitumor Activity of Novel Water Soluble Derivative of Camptothecin Against Murine Tumors. Cancer Res. 47:5944-5947, 1987.
Luzzio, M.J., et al., Synthesis and Antitumor Activity of Novel Water Soluble Derivatives of Camptothecin as Specific Inhibitors of Topoisomerase I. J. Med. Chem. 38: 395-401, 1995.
Malone et al., Desoxycholic Acid Enhancement of Orally Administered Reserpine. Journal of Pharmaceutical Sciences, 55:972-974 (1966).
Masuda, N., et al., CPT-11: A New Derivative of Camptothecin for the Treatment of Refractory or Relapsed Small-Cell Lung Cancer. J. Clin. Onc. 10(8): 1225-1229, 1992.
Moertel, C.G. et al., Phase II Study of Camptothecin (NSC-100880) in the Treatment of Advanced Gastrointestinal Cancer. Cancer Chem. Rep. 56: 95-101, 1972.
Muggia, F.M. et al., Phase I Clinical Trial of Weekly and Daily Treatment with Camptothecin (NSC-100880): Correlation with Preclinical Studies. Cancer Chem. Rep. 56:515-521, 1972.
Negoro, S. et al., Phase I Study of Weekly Intravenous Infusions of CPT-11, a New Derivative of Camptothecin, in the Treatment of Advanced Non-Small Cell Lung Cancer. JNCI 83(16): 1164-1168, 1991.
Negoro, S., et al., Phase II Study of CPT-11, New Camptothecin Derivative, in Small Cell Lung Cancer. Proc. Of Amer. Soc. Clin. Onc. 10:241, 1991.
Niimi, S., et al., Mechanism of Cross-Resistance to a Camptothecin Analogue (CPT-11) in a Human Ovarian Cancer Cell Line Selected by Cisplatin. Cancer Res. 52: 328-333; 1992.
Ohe, Y., et al., Phase I Study and Pharmacokinetics of CPT-11 with 5-Day Continuous Infusion. JNCI 84(12): 972-974, 1992.
Ohno, R. et al., An Early Phase II Study of CPT-11: A New Derivative of Camptothecin, for the Treatment of Leukemia and Lymphoma. J. Clin. Onc. 8(11): 1907-1912, 1990.
Pantazis, P. et al., Cytotoxic Efficacy of 9-Nitrocamptothecin in the Treatment of Human Malignant Melanoma Cells in Vitro. Cancer Research. 54: 771-776, 1994.
Pommier, Y. et al., Camptothecins: Mechanism of Action and Resistance (Meeting Abstract). Cancer Investigation, Presented at the "Chemotherapy Foundation Symposium X Innovative Cancer Chemotherapy for Tomorrow", p. 3, 1992.
Potmesil, M. et al., Preclinical and Clinical Development of DNA Topoisomerase I Inhibitors in the United States. In Andoh, T., Ikeda, H., Oguro, M. (editors): Molecular Biology of DNA Topoisomerases and Its Application to Chemotherapy. Boca Raton, FL, CRC Press, Inc. 301-311, 1993.
Rivory, L.P., et al., Kinetics of the in Vivo Interconversion of the Carboxylate and Lactone Forms of Irinotecan (CPT-11) and of Its Metabolite SN-38 in Patients. Cancer Research. 54:6330-6333, 1994.
Rothenberg, M.L. et al., A Phase I and Pharmacokinetic Trial of CPT-11 in Patients with Refractory Solid Tumors. Amer. Soc. Clin. Onc. 11:113, 1992.
Rothenberg, M.L., Kuhn, J.G., Burris, H.A., Nelson, J., Eckardt, J.R., Tristan-Morales, M., Hilsenbeck, S.G., Weiss, G.R., Smith, L.S., Rodriguez, G.I., Rock, M.K., Von Hoff, D.D. Phase I and Pharmacokinetic Trial of Weekly CPT-11. Journal of Clinical Oncology. 11:2194-2204 (1993).
Rowinsky, E. et al., Phase I Pharmacologic Study of CPT-11, A Semisynthetic Topoisomerase I-Targeting Agent, on a Single-Dose Schedule (Meeting Abstract). Proc. Of Amer. Soc. Clin. Onc. 11:115, 1992.
Sawada, S., et al., Synthesis and Antitumor Activity of 20 (S) - Camptothecin Derivatives: Carbonate-Linked, Water Soluble, Derivatives of 7-Erthyl-10-hydroxycamptothecin. Chem. Pharm. Bull. 39:1446-1454; 1991.
Shimada, Y. et al., Phase II Study of CPT-11, New Camptothecin Derivative, In the Patients with Metastatic Colorectal Cancer. Proc of Amer. Soc. Clin. Onc. 10:135, 1991.
Supko, J.G. et al., Pharmacokinetics of the 9-Amino and 10,11-Methylenedioxy Derivatives of Camptothecin in Mice. Cancer Research 53: 3062-3069, 1993.
Takeuchi, S. et al., Late Phase II Study of CPT-11, A Topoisomerase I Inhibitor, In Advanced Cervical Carcinoma (CC) (Meeting Abstract). Proc. Of Amer. Soc. Clin. Onc. 11:224, 1992.
Wall, M.E. et al., Camptothecin and Taxol: Discovery to Clinic-Thirteenth Bruce F. Cain Memorial Award Lecture. Cancer Research. 55:753-760, 1995.
Wall, M.E,
Haridas Kochat
Hausheer Frederick H.
Murali Dhanabalan
Reddy Dasharatha Gauravaram
BioNumerik Pharmaceuticals, Inc.
Cook Rebecca
Dodd Thomas J.
LandOfFree
Pharmaceutical formulations of highly lipophilic camptothecin de does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical formulations of highly lipophilic camptothecin de, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical formulations of highly lipophilic camptothecin de will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1321394